Previous 10 | Next 10 |
2023-12-20 13:13:03 ET Gainers: Polished.com ( POL ) +590% . ParaZero Technologies Ltd ( PRZO ) +75% . Liquidia Corp ( LQDA ) +37% . Ebang International Holdings ( EBON ) +35% . ECARX Holdings ( ECX ) +36% . Mawson Infrastruc...
Enrollment completed in placebo-controlled, randomized, dose-finding, multi-country, multi-center Phase II sepsis study Topline Data Expected in late Q1 2024 Nes-Ziona, Israel, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a...
YAVNE, Israel, Nov. 21, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, today announced the appointment of Shmulik Hess, Ph.D. to the positions of Chief Operating Officer and ...
2023-11-03 12:39:12 ET Gainers: Cooper-Standard Holdings CPS +42% . Udemy UDMY +37% . DarioHealth Corp ( DRIO ) +37% . Qurate Retail QRTEP +29% . Enlivex Therapeutics Ltd ( ENLV ) +28% . Redfin Corp RDFN +28% . Figs FIGS +27% ...
2023-10-09 13:00:03 ET More on InMode, Nano-X, etc. Full Of Potential Red Flags: Breaking Down Nano-X Imaging Nano-X Imaging: Cash Burn Makes It A Hold InMode: Bullish Support Failed To Materialize War between Israel and Hamas pushes U.S.-traded Israeli stock...
The Company intends to increase its existing focus on inflammatory and autoimmune indications. The Company, since its inception, considered the inherent properties of Allocetra TM as an innovative, highly-differentiated modality for immune resolution across a wide variety of inflammatory and ...
Nes-Ziona, Israel, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage macrophage reprogramming immunotherapy company, today announced that company management will present a corporate update at the H.C. Wainwright 25th Annual Global Investment Conference,...
American Bio Medica Corp. (ABMC) is expected to report for Q1 2024 Fonar Corporation (FONR) is expected to report for Q1 2024 Bank Hapoalim B.M. ADR (BKHYY) is expected to report for Q2 2023 QualTek Services Inc. (QTEKQ) is expected to report for Q2 2023 BIMI International Medical...
Enlivex Therapeutics Ltd. (ENLV) is expected to report $-0.43 for Q2 2023
Data published in Frontiers in Immunology show a robust safety profile and rapid resolution from ARDS and parallel resolution of inflammation markers and elevated cytokines/chemokines, as well as substantial improvements in mortality in 21 Allocetra-treated patients with COVID-19 vs. matched hist...
News, Short Squeeze, Breakout and More Instantly...
Enlivex Therapeutics Ltd. Company Name:
ENLV Stock Symbol:
NYSE Market:
Enlivex Therapeutics Ltd. Website:
First patient dosed with Allocetra TM in thumb osteoarthritis, a degenerative, debilitating and progressive disease that affects millions of people Thumb osteoarthritis currently has no FDA-approved therapy and no effective long-term treatments Ness-Ziona, Israel, June 24, 2024 (GLO...
Ness-Ziona, Israel, June 20, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company” or “Enlivex”), a clinical-stage macrophage reprogramming immunotherapy company, is pleased to invite investors to a webinar on June 25, 2024, at 4:15 p.m...
Key Highlights Enrolled patients with severe knee osteoarthritis who were indicated for knee-replacement surgery received a single local injection of Allocetra TM into the knee as a “last resort” Three-month data readout showed a significant reduction in pain and a f...